Evidence map›Paper›PMID 33603155›Full record

ArticleCommunications biology2021

PANDAA intentionally violates conventional qPCR design to enable durable, mismatch-agnostic detection of highly polymorphic pathogens.

Iain J MacLeod, Christopher F Rowley, M Essex

Abstract read
In one paragraph

Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Iain J MacLeodDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA. iam391@mail.harvard.edu.ORCID 0000-0001-5608-634X
Christopher F RowleyDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.
M EssexDepartment of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, MA, USA.

Funding

Novel Strategy for HIV Drug Resistance Monitoring in Developing Countries.R01AI089350 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI ROWLEY, CHRISTOPHER F · 2011 to 2014
$1.2M
NIAID NIH HHS R01 AI089350
6 · The paper itself

Abstract

Sensitive and reproducible diagnostics are fundamental to containing the spread of existing and emerging pathogens. Despite the reliance of clinical virology on qPCR, technical challenges persist that compromise their reliability for sustainable epidemic containment as sequence instability in probe-binding regions produces false-negative results. We systematically violated canonical qPCR design principles to develop a Pan-Degenerate Amplification and Adaptation (PANDAA), a point mutation assay that mitigates the impact of sequence variation on probe-based qPCR performance. Using HIV-1 as a model system, we optimized and validated PANDAA to detect HIV drug resistance mutations (DRMs). Ultra-degenerate primers with 3' termini overlapping the probe-binding site adapt the target through site-directed mutagenesis during qPCR to replace DRM-proximal sequence variation. PANDAA-quantified DRMs present at frequency ≥5% (2 h from nucleic acid to result) with a sensitivity and specificity of 96.9% and 97.5%, respectively. PANDAA is an innovative advancement with applicability to any pathogen where target-proximal genetic variability hinders diagnostic development.

Indexed as

DNA PrimersPoint MutationPolymerase Chain ReactionAnti-HIV AgentsDNA, ViralDrug Resistance, ViralEfavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationGenotypeHigh-Throughput Nucleotide SequencingHIV-1HIV InfectionsHumansReproducibility of ResultsVirologyAnti-HIV AgentsDNA PrimersDNA, ViralEfavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination

Identifiers

PMID33603155
PMCPMC7892852

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.